Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy: current status.
This article reviews aetiology, natural history, and current treatment options in hypertrophic cardiomyopathy with a special focus on percutaneous septal ablation, which has evolved as an alternative to myectomy in patients with outflow obstruction and symptoms refractory to medical treatment. Literature data and the own series of 382 interventions (in-hospital mortality and pacemaker implantation rates: 1.2% and 7%, respectively) are discussed. Overall satisfactory clinical results were seen in about 90% of the patients treated with septal ablation.
Faber
Lothar
L
Department of Cardiology, Heart and Diabetes Centre North Rhine-Westphalia, University Hospital of the Ruhr University Bochum, D-32545 Bad Oeynhausen, Germany.
Welge
Dirk
D
Fassbender
Dieter
D
Buschler
Helga
H
Schmidt
Henning K
HK
Horstkotte
Dieter
D